Case Presentation: An 83-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

In an interview with Targeted Oncology, Nasir Chaudry, MD, discussed the evolving landscape of prostate cancer treatment, driven by new research.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.

The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.